(Circulation. 1995;92:1336-1347.)
© 1995 American Heart Association, Inc.
Articles |
Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy
From the Department of Medicine, Section of Cardiology, Baylor College of Medicine, Houston, Tex.
Correspondence to Robert Roberts, MD, Section of Cardiology, Baylor College of Medicine, 6535 Fannin, MS F905, Houston, TX 77030.
Key Words: genetics • molecular biology • hypertrophy • cardiomyopathy
 |
Introduction |
|---|
 Top Introduction Clinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The recent evolution of molecular genetic techniques and their application in deciphering the molecular genetic basis of inherited diseases have facilitated the dawning of molecular medicine. A complete genetic map of the human genome, based on easily identifiable highly polymorphic DNA markers, has been developed.1 2 3 This achievement is a milestone in that it provides the foundation for genetic linkage analysis, a technique essential to the mapping of the chromosomal locus responsible for a disease. Before the development of multiple informative markers, identification of a disease-related gene required a priori knowledge of the defective protein, which was known for only a few diseases. The previous approach of "from a defective protein to a defective gene" has been replaced with the approach of "from a defective gene to a defective protein." The recent availability of the highly informative STRP markers compared with previous markers based on RFLP has greatly accelerated chromosomal mapping by linkage analysis.4 Furthermore, the RFLP markers detected by Southern blotting required 5 to 7 days, whereas STRP markers are detected by PCR and require as few as 1 to 2 days.4 5 The loci for more than 400 disease-related genes have been mapped, and the responsible genes have been identified for more than 40 of these diseases.1 Theoretically, it is possible to map the chromosomal locus of any disease-related gene if a family with 10 or more living affected individuals spanning two or more generations is available.4 5 Subsequent to the chromosomal mapping of the locus by genetic linkage analysis, several techniques, such as positional cloning, are used to identify the responsible gene.6 7 Positional cloning refers to cloning of a segment of DNA with only its chromosomal position in relation to a marker known. This process of identifying the genes, which may require years, has been accelerated recently through the development of two techniques: YAC and PFGE.8 Before the availability of YAC, one could clone fragments of DNA only as large as 45 000 bp, whereas with YAC, it is possible to clone fragments as large as 1 to 2 million bp. Separation of DNA fragments by agarose gel electrophoresis was limited to those of
10 000 bp, whereas with
PFGE, fragments as large as 2 million bp can be separated. HCM was the first primary cardiomyopathy that was subjected to these techniques. During the short period of 4 years, three genes and a fourth locus responsible for this disease have been identified.9 10 11 12 In addition, structure-function analysis has shed significant light on the molecular basis of this disease. It is hoped that within the next few years the application of molecular genetic tools will not only facilitate the ability to diagnose HCM but also help to stratify and develop more definitive therapy.
|
Clinical Epidemiology |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Familial HCM is inherited as an autosomal dominant disease that is characterized by hypertrophy, often of the left ventricle, with predominant involvement of the interventricular septum in the absence of other causes of hypertrophy, such as hypertension or valvular heart disease.13 The predominant cardiac pathology is myocyte hypertrophy and sarcomere disarray; the former is found in most cardiac diseases, whereas the latter is the hallmark of HCM.14 The ventricular systolic function is usually normal or supernormal, with an average left ventricular ejection fraction of 65% to 70%. However, ventricular diastolic function often is impaired in patients with HCM. The clinical manifestations of HCM are diverse, ranging from a benign asymptomatic course to severe heart failure and SCD.13 SCD is a well-recognized outcome of HCM. The annual incidence of SCD is higher in younger patients with HCM (6%) than in the elderly (1%).15 16 17 In young, apparently healthy athletes with HCM, SCD often is the first manifestation of the disease.15 16 17 In a study of 29 highly conditioned young (<35 years old) athletes who died suddenly, HCM was present at autopsy in 48% of the cases, and idiopathic left ventricular hypertrophy (probably HCM) was present in an additional 18% of the cases.17
The true prevalence of HCM remains unknown. Clinical diagnostic criteria probably underestimate the prevalence of the disease as the phenotypic expression of the disease (ie, development of hypertrophy) is age dependent.18 The presence of concomitant diseases such as hypertension and valvular heart disease also confounds the diagnosis of HCM.19 Several investigators have estimated the prevalence of the disease to be approximately 0.1 to 1 per 1000 population.20 21 22 23 24 The prevalence of the disease is higher in older individuals and in those with an abnormal ECG.23 24 In a study of 3607 men (452 men with ECG abnormalities and 3155 men with no ECG abnormalities), the overall prevalence of HCM was 1.1% in the study group, 0.8% in those with no ECG abnormalities, and 3.6% in those with ECG abnormalities.23 This probably reflects the fact that HCM is often associated with ECG abnormalities.
|
Genetic Basis of HCM |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The disease was first described in the 19th century,25 but it was not until 1958 that Teare described the familial inheritance of HCM.26 Braunwald et al in 196427 and Frank et al in 196828 described several families with HCM, and they further delineated its familial nature. Clark et al29 and van Dorp et al30 performed routine echocardiography on all family members of patients with HCM and showed that the pattern of inheritance of HCM was autosomal dominant with a high but variable degree of penetrance. Echocardiographic screening of the families in their studies showed that cardiac hypertrophy was present in many asymptomatic relatives of the affected individuals.29 The data, indicating that 55% of the cases of HCM are familial and the remainder are sporadic, may have to be reevaluated once genetic screening becomes routinely available.31 32 Essentially, HCM is always a genetic disorder. When de novo mutations occur, the disease may not be transmitted to offspring in a small family as each offspring has only a 50% chance of inheriting the mutation. Thus, despite being an underlying genetic cause of HCM, the disease may not exhibit familial inheritance. It is clear that many ß-MHC mutations occur spontaneously and have an independent origin.33
In 1989, Jarcho et al34 applied linkage analysis
to a large French Canadian family and showed linkage of the disease to
the chromosomal locus of 14q1. Through similar studies, Hejtmancik et
al35 showed that the chromosome 14 locus was linked to HCM
in several families from North America. The ß-MHC gene was
identified as the responsible gene, and several mutations were shown to
co-segregate with inheritance of the disease, suggesting a causal
role for ß-MHC in these families as well as confirming an
autosomal dominant pattern of inheritance.36 37 The
first
mutation identified was that of a missense mutation in which A
substituted for G in exon 13, resulting in a change in the coding of
arginine for glutamine.36 Subsequently, at least 36
mutations in the ß-MHC gene have been shown to be
responsible for HCM, and these mutations have been reported
worldwide in families with
HCM5 36 37 38 39 40 41
(Table 1
).
|
Several families, however, have been identified who did not show
linkage to chromosome 14q1.42 43 44 Two
new chromosomal loci
responsible for HCM have been mapped9 10 to 1q3 and
15q2,
and the responsible genes are cardiac troponin T and
-tropomyosin,12 respectively (Table
2). A fourth locus has been mapped, 11q11, but the gene
has not been identified.11 Mutations in the cardiac
troponin T and the -tropomyosin genes have been
identified that co-segregate with inheritance of the
disease12 (Table 1
). It appears that the mutations
in the
ß-MHC gene occur in approximately 20% to 30% of the
families with HCM.45 However, the true incidence of
ß-MHC mutations and of mutations in cardiac troponin
T, -tropomyosin, and additional genes remains
unknown. Furthermore, linkage to a fragile site on chromosome 16 and
linkage to the prealbumin gene on chromosome 18 have been
reported without identification of the responsible
genes.46 47 Thus, HCM exhibits genetic
heterogeneity with regard to both the number of
responsible genes and the number of mutations. It is highly likely that
many genes responsible for HCM remain to be identified.
|
|
ß-MHC Protein and Its Role in the Sarcomere |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The ß-MHC gene on chromosome 14 is separated from the
-MHC gene by only 3.5 kb DNA.48 It is
composed of 40 exons that span approximately 23 kb of the
genome.49 50 The mature ß-MHC mRNA is
6008 bp
and encodes for a protein with a molecular weight of 220 kD. The
ß-MHC is the contractile protein of the heart with enzymatic activity
that in the presence of actin hydrolyzes ATP to ADP and Pi.
The ß-MHC protein is divided into three functional segments referred
to as the globular head, hinge region, and rod segment. The first 23
exons of the ß-MHC gene encode for the globular head and
hinge regions of the protein, whereas the remaining exons encode for
the rod portion of the ß-MHC protein. The globular head of the myosin
molecule contains the major domains of the protein, such as actin and
ATP-binding sites. The hinge region flexes during cardiac contraction,
contracting from a 90° angle to a 45° angle, which, in turn, pulls
the actin filaments toward the center, resulting in shortening
(contraction). The rod is essential for tail-to-tail
interbinding of the myosin molecules that form the thick filament. The
rod, a coiled helix, also coils around the rod of another ß-MHC
molecule, with the two heads separated and folded backward onto each
other to form a globular shape. Attached to each ß-MHC head are one
regulatory and one essential myosin light chain molecule, which
together form a hexameric protein. Each thick filament of the sarcomere
is formed from more than 400 ß-MHC molecules bound together by their
tails (Fig 1).
|
The ß-MHC protein is the major contractile protein of the sarcomere
and makes up approximately 30% of the myocardial
protein.51 52 It is the predominant protein in the
cardiac
ventricles of large mammals as it is in the adult human heart,
comprising more than 95% of the myosin in the human
ventricles.51 52 The three-dimensional structure of
the S1 fragment of the myosin molecule (globular head and myosin light
chains) has been determined from atomic resolution after the molecule
was crystallized.53 ATP binds to a small groove in the
globular head of the myosin molecule, which results in detachment of
the myosin molecule from actin.54 Enzymatic activity of
the myosin ATPase results in hydrolysis of ATP to ADP and
Pi, and with removal of the latter end products,
flexion of the hinge region of the myosin molecule occurs that
displaces the globular head over the actin filaments (contraction and
cardiac systole). Subsequently, ATP is again taken up into the groove,
and myosin is again released from the actin filaments (Fig 2).
New techniques have been developed that can
accurately quantify the movement of a single myosin head over an actin
filament during contraction.54 55 56
These data indicate that
each myosin molecule is capable of generating a force of 
10 pN,
which results in approximately 12-nm displacement of the globular head
over the actin filament during each contraction.55 56
|
|
ß-MHC Gene Mutations |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
A large number of mutations in the ß-MHC gene have been identified and shown to co-segregate with inheritance of the disease.5 36 37 38 39 40 41 All of the mutations of the ß-MHC gene except one are missense mutations located within the first 23 exons that encode for the globular head of the ß-MHC protein. Although Arg403Gln (G1208A in exon 13) is the most commonly described mutation in families with HCM and the 403 codon is considered a hot spot for mutations,40 no single mutation appears to be predominant in HCM. The majority of the ß-MHC mutations involve replacement of guanine or cytosine nucleotides, as expected, and involve an evolutionary conserved amino acid. Only one mutation encoding for the rod region has been described39 ; this was a deletion mutation that deletes part of intron 39, exon 40, and the entire 3' untranslated region.39 In the ß-MHC protein, the deletion mutation results in deletion of the last five amino acids in the C-terminus. The C-terminus of the ß-MHC protein is essential for tail-to-tail interbinding of the myosin molecules to form the thick filament of the sarcomere. Haplotype analysis of families with HCM who have identical mutations has indicated an independent origin of the ß-MHC mutations in these families33 rather than arising from a single founder. This indicates that the ß-MHC gene is highly vulnerable to mutagenesis, and one would expect to find many new mutations arising sporadically.
|
Cardiac Troponin T and -Tropomyosin
Genes and Proteins
|
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The cardiac troponin T gene, which is located on chromosome 1q3,12 is composed of 15 exons and transcribes a mature mRNA of approximately 1.2 kb.57 The cardiac troponin T gene undergoes multiple alternative splicing, resulting in several isoforms of cardiac troponin T.58 Expression of cardiac troponin T is developmentally regulated.58 Cardiac troponin T comprises approximately 5% of the total myofibrillar protein and, along with troponin I and troponin C, is involved in Ca2+ regulation.59 Troponin T binds to tropomyosin and is responsible for positioning of the troponin complex on the thin filaments.
Thus far, seven missense mutations and a deletion mutation in the
cardiac troponin T gene have been identified in patients
with HCM.12 60 The missense mutations are located in
exons
8, 9, 11, 14, and 16. The deletion mutation is a 5' splice donor site
G
A transition in residue 1 of intron 15, which is expected to
produce a truncated cardiac troponin T with loss of the
terminal 28 amino acid residues. The 5' splice donor mutation is likely
to function as a null allele and result in synthesis of a truncated
troponin T that degrades rapidly. A decreased quantity of
stable cardiac troponin T is likely to alter the
stoichiometry of the sarcomeric proteins, which could be responsible
for the phenotype of HCM. The truncated cardiac troponin
T mutation is the second deletion mutation described in families
with HCM.12 39 The first deletion mutation described
in a
family with HCM was a deletion mutation in the 3' region of the
ß-MHC gene, which is also postulated to result in
expression of a truncated unstable message.39 These
mutations in the cardiac troponin T gene appear to be
uncommon mutations in families with HCM. In addition, screening for
cardiac troponin T gene mutations in families with HCM
indicates that such mutations account for HCM in 15% of affected
families.60
-Tropomyosin protein is a rod-shaped sarcomeric protein that
comprises approximately 5% of the total myofibrillar
protein.59 Each -tropomyosin binds to another
molecule in an helix coil, forming a dimer, which is the functional
form of the protein. The function of-tropomyosin is to
bridge the binding of the troponin protein complex to thin actin
filament.59 The gene for-tropomyosin is
located on chromosome 15q2 and is composed of 15 exons with the
corresponding mature mRNA of 1 kb.59 Two missense
mutations have been described in exon 5 of the
-tropomyosin gene in affected individuals from families
with HCM. The first mutation is due to substitution of adenine for
guanine at position 579, which alters the amino acid sequence from
aspartic acid to asparagine at position 175
(Asp175Asn).12 The second missense mutation is
an AG substitution at position 595, which changes the glutamic acid
residue at amino acid 180 to a glycine residue. Fewer than 5% of cases
of HCM are caused by mutations in -tropomyosin
gene.60
|
Evidence That ß-MHC Mutations Are Responsible for HCM |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The evidence that mutations in the ß-MHC gene are responsible for the disease in families with the mutation is conclusive: (1) multiple families have been shown to be genetically linked to the ß-MHC locus on chromosome 14; (2) DNA analysis shows that each affected individual within a single family has the same mutation, which is not present in the unaffected individuals; (3) ß-MHC mutations are absent in the general population; and (4) ß-MHC mutations are expressed in the cardiac mRNA and protein of individuals affected with HCM. Perryman et al61 showed that the Arg403Gln mutation was expressed in the mRNA extracted from the myocardium of a patient with HCM, and Greve et al62 showed expression of Arg741Lys in the mRNA and protein in the explanted heart of a patient with sporadic HCM. Yu et al63 showed expression of the ß-MHC mutation Arg403Gln in mRNA extracted from skeletal muscle, and Cuda et al64 65 isolated several different mutant ß-MHC proteins from skeletal muscle of patients with HCM. (5) De novo mutations occurring in the ß-MHC gene have been shown to result in transmittal of the disease to offspring. Greve et al62 showed that the mutation Arg741Lys, which was proved by haplotyping to occur de novo, was transmitted to two subsequent generations and induced the disease in an autosomal dominant manner. Furthermore, the explanted heart from the proband showed expression of the mutation in the cardiac mRNA and protein. These studies provide conclusive evidence that ß-MHC mutations are responsible for HCM in these families. In addition, a de novo mutation in
-tropomyosin that causes HCM has also been
reported.66 (6) In vitro motility studies (discussed
later) show the mutant ß-MHC protein to have impaired contractile
function and decreased actin-dependent ATPase
activity.67 (7) Expression of the mutant human
ß-MHC gene with the Arg403Gln mutation in
feline adult cardiac myocytes was associated with disarray of the
sarcomeres68 (discussed later). |
Genotype-Phenotype Correlation in HCM |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
The consistent phenotype of patients with HCM is cardiac hypertrophy, which predominantly affects the interventricular septum. However, the degree of hypertrophy, its distribution, patient age at onset, and type and severity of clinical manifestations vary markedly. The natural course of HCM in certain families is riddled with SCD, whereas in others SCD is almost absent, and the life span is essentially normal.69 Identification of the underlying genetic defect provides the opportunity to relate phenotype to specific genotypes. Results of these studies indicate70 that in the majority of families described, the ß-MHC mutations Arg403Gln, Arg453Cys, and Arg719Trp are associated with a poor prognosis and a high incidence of SCD.38 71 72 73 74 75 In contrast, the ß-MHC mutation Leu908Val is associated with a near-normal life expectancy.74 In addition, the mutations Glu930Lys and Arg249Gln are associated with an intermediary risk of SCD.38 75
The phenotypes associated with Arg403Gln have been described in several families with HCM and are characterized by high penetrance, a high incidence of SCD, and severe hypertrophy.38 72 73 In the majority of families described, the incidence of premature death in affected individuals with Arg403Gln mutations is approximately 50%.75 We identified two families with the Arg403Gln mutation in whom 11 of the 20 affected individuals died prematurely—9 from SCD.75 The mean age at the time of SCD was 33 years. There also was an early onset of symptoms, a high penetrance, and a high prevalence of ECG and echocardiographic abnormalities. Watkins et al38 observed a high incidence of SCD in two families with the Arg403Gln mutation in whom 21 of 44 affected individuals died prematurely—9 from SCD, at a mean age of 33±15 years. A third group of investigators reported two families with HCM who had the Arg403Gln mutation.73 74 In both families, there was a high penetrance and a high incidence of myocardial ischemia, but the survival rates of affected individuals in these two families were different. In the white family, SCD occurred in 6 of the 15 affected individuals between the ages of 19 and 45 years, resulting in a cumulative SCD rate at 40 years of age of 45%. In contrast, in the Korean family with the Arg403Gln mutation, none of the 6 affected individuals had died. The variability in the incidence of SCD in two families with the identical mutation may in part reflect the different genetic background of these families or the small size of the Korean family, which precludes meaningful assessment of survival rate.
A second ß-MHC mutation associated with a high incidence of SCD is Arg719Gln, which has been described in four families composed of 61 individuals.76 Thirty-five of the 61 affected individuals with Arg719Gln mutation have died—22 from SCD.71 The life expectancy of the affected individuals in these four families was 38 years. The Arg453Cys mutation is another malignant mutation that has been described in one family in whom 9 of the 13 affected individuals have died—6 from SCD.38 The mean age at the time of death of the affected individuals was 30±12 years.
The Leu908Val mutation has been associated with a low penetrance, a benign course, and a low incidence of SCD.73 The genotype-phenotype correlation was described in a large family with HCM composed of 46 genotype-positive individuals, only 2 of whom have died.73 The cumulative survival rate at 60 years of age was 92%. Similarly, the Gly256Glu mutation has been associated with a benign prognosis in a large family with HCM composed of 39 affected individuals.74 The cumulative SCD rate at age 50 in the affected individuals with the Gly256Glu mutation was only 2%. The Val606Met mutation has also been associated with a benign prognosis in four families with HCM.38 72 Watkins et al38 reported the Val606Met mutation in three small families composed of 18 affected individuals, 1 of whom has died. We identified the Val606Met mutation in a family with HCM composed of 12 affected individuals, only 1 of whom has died.72 However, Fananapazir et al74 reported a family with the Val606Met mutation in whom there is a severe form of the disease and a high incidence of SCD. These correlations must be interpreted with caution as the number of families studied remains too small for definitive conclusions to be made.
Two mutations have been characterized as being associated with an intermediary prognosis: the Glu930Lys and Arg249Gln mutations.38 75 We described a family composed of 16 affected individuals with Glu930Lys mutation 2 of whom have died at ages 14 and 16 and 1 had undergone cardiac transplantation due to progressive heart failure at age 58. The ß-MHC mutation Arg249Gln has been described in a family composed of 26 affected individuals, 10 of whom have died—4 from SCD.38 The average age of the affected individuals at the time of death was 49 years.38
Echocardiography is the most sensitive and specific clinical method of diagnosing HCM. The diagnosis is based on echocardiographic detection of cardiac hypertrophy in the absence of other causes for hypertrophy, such as hypertension or valvular disease.35 However, hypertrophy is not usually evident before puberty and, when the penetrance is low, may not develop until middle age.18 20 39 In individuals with other causes for hypertrophy or in the elderly, the echocardiographic detection of hypertrophy is inconclusive, and only a genetic diagnosis is definitive. Mutations with low penetrance will characteristically provide families with many individuals who have the defective genotype but no disease that can be detected with the use of echocardiography. In a study by Solomon et al,32 a considerable overlap was present in the left ventricular wall thickness between genotype-positive individuals and genotype-negative individuals. Thus, in these situations, echocardiography is inadequate for the diagnosis of HCM.32 Individuals with the same HCM genotype have a broad spectrum of echocardiographic findings, but the presence and extent of hypertrophy on the echocardiogram are reflective of clinical severity. Mutations that are associated with high penetrance and poor prognosis are more likely to show a greater degree of left ventricular hypertrophy or septal thickness than are those associated with low penetrance and good prognosis.32 72 73 74 75 In our preliminary research, the mean septal thickness as measured with echocardiography for 14 patients with HCM due to the Arg403Gln mutation (associated with a poor prognosis) was 18.1±6.4 mm, whereas in 9 patients with the benign Val606Met mutation,72 the mean septal thickness was 13.3±3.9 mm (P=.04). Similarly, we found that the left ventricular mass index was greater in patients with the Arg719Trp mutation than in those with the Val606Met mutation (unpublished data). Large-scale analysis is required to verify these preliminary findings and to characterize the diagnostic and prognostic implications of echocardiographic findings in the context of each mutation.
Two additional genes for HCM have been described—cardiac
troponin T and -tropomyosin, as well as a fourth
locus, to be discussed. The spectrum of clinical manifestations
observed in these families is similar to that caused by the
ß-MHC gene.9 10 11
Genotype-phenotype correlations of cardiac troponin
T mutations show the presence of relatively mild and sometimes
subclinical hypertrophy but a high incidence of SCD.
|
Influence of Environmental Factors and Genetic Background on Phenotypic Expression of HCM Mutations |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Even within the same family, the phenotypic expression of HCM among affected individuals sharing the same mutation varies markedly, indicating a role for environmental factors and possibly other genetic factors. The most striking example to indicate an environmental effect is the observation that despite ß-MHC being expressed similarly in the right and left ventricles, HCM is primarily a disease of the left ventricle. Hypertrophy presumably occurs in response to the higher systolic pressure in the left ventricle.
There also is evidence suggesting that other genetic factors play a
role in the expression of cardiac hypertrophy associated
with HCM. ACE genotype DD (rather than
ID or II) was found to be more common in patients
from families with HCM, showing a malignant phenotype
characterized by a high incidence of SCD.77 We have shown
in a study of 120 patients with HCM that a left ventricular
mass index of 
100 g/m2 (defined as an increased mass
index) was six times more likely to occur in patients with the
ACE genotype DD than in those with the
ACE genotype II.78
Furthermore, the ACE genotype DD was
associated with more extensive left ventricular
hypertrophy characterized by involvement of the entire
interventricular septum, apex, and lateral
wall.78 The genotypes of the ACE gene
DD, II, and ID, are independent of the genes
responsible for HCM, but in an individual with HCM
genotype who also has the ACE genotype
DD, hypertrophy is more likely to be manifested
and to be more extensive than if the genotype is II.
It appears that genotypes such as DD may have a
significant role in the degree of penetrance and the variation in
phenotype (expressivity) observed in patients with HCM.
Hypertrophy requires the coordination of a large number of
genes, and thus, it is highly likely that many other genes such as the
ACE genotypes influence expressivity of the primary
genetic defect. It should not be concluded that the DD
allele is necessarily causative of the hypertrophy as
it may simply reflect a more important causative gene that is located
in close proximity. However, the finding that ACE
genotype DD influences the phenotypic expression of
HCM, probably through the mitogenic effect of
angiotensin II,79 raises the intriguing
question of the role of ACE inhibitors in HCM. It is now
well established that ACE inhibitors induce regression of
hypertrophy due to pressure overload, independent of
afterload.80 It is intriguing whether ACE
inhibitors could also induce regression of
hypertrophy in patients with HCM. The data are inadequate
to recommend such therapy for HCM at this time, and should such therapy
be used in the future, it might be contraindicated in patients with
outflow tract obstruction. Nevertheless, ACE inhibitors
have recently been shown to improve diastolic function in
patients with aortic stenosis.81 However, the
knowledge that angiotensin II is a mitogen that induces
cardiac hypertrophy and that ACE inhibitors
have been shown to induce regression of hypertrophy makes
this observation worth pursuing, since ACE inhibitors may
be beneficial.
|
Structure-Function Analysis of ß-MHC Mutations to Identify the Primary Defect |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Studies are under way to determine the primary defect initiated by the mutations that lead to the phenotype of HCM. It is most appropriate to concentrate on the myocardial lesion of hypertrophy since the heart is the only organ responsible for the phenotype. Hypertrophy, along with myocyte and sarcomere disarray, is associated with normal systolic but impaired diastolic function. Three of these studies have used a recently developed in vitro motility assay to assess the effect of the mutation on the contractile properties of the ß-MHC protein. In this assay, microscopic beads are coated with actin, and the myosin globular head is fixed to a nitrocellulose membrane. The extent to which myosin moves the beads on binding with actin is detected with a laser beam. The displacement of the bead for each individual myosin molecule averages 10 nm with an average force of 10 pN.54 55 56 Cuda et al64 isolated the ß-MHC protein from skeletal muscle of patients with HCM and showed that the velocity of contraction was significantly less than that of ß-MHC isolated from skeletal muscle of unaffected individuals. Furthermore, Cuda et al65 demonstrated that the degree of impairment of velocity of the contraction varied with the site of mutation. The results of these studies were corroborated by Sweeney et al67 with in vitro expression of rat cardiac
-myosin that was mutated in a region
homologous to that of the human mutation (Arg403Gln) in the
ß-MHC gene. A normal and a mutant (Arg403Gln)
full-length rat -cardiac myosin were expressed in Sf9 cells,
and the heavy meromyosin fragment was isolated for in vitro motility
studies. The mutant fragment showed an approximately fivefold reduction
in the rate of displacement of actin filaments compared with the normal
fragment.67 Furthermore, by mixing different ratios of
normal and mutant fragments, they showed that the mutant myosin
disproportionately reduced the velocity of actin displacement. In these
experiments, an increase in the ratio of mutant to normal myosin to
50% reduced the rate of actin filament displacement to 20% of
control. The actin-activated ATPase activity of the mutant
(Arg403Gln) fragment was also significantly reduced
compared with control. Lankford et al82 compared the force-velocity relationship and power output of single slow-twitch muscle fibers isolated from the soleus muscle of patients with three distinct ß-MHC gene mutations. They showed that fibers with Arg403Gln and Gly741Arg exhibited a significantly reduced maximum velocity of shortening and isometric force generation. In contrast, fibers containing the Gly256Gln mutation displayed essentially normal contractile properties.
Straceski et al83 studied the formation of microfilaments
in COS cells after expression of normal and mutant rat -MHC
constructs. COS cells normally do not form filamentous structure;
however, expression of the normal rat cardiac -myosin in COS
cells resulted in formation of structures similar to thick
filaments84 in 25% of the transfected cells, whereas the
mutant -MHC showed filament-like structures in only
2% of the transfected cells.83
To determine whether the sarcomere disarray observed in the myocardium of patients affected with HCM was the primary lesion resulting from ß-MHC mutations, we selected feline cardiac myocytes because they normally form sarcomeres as their contractile unit and have ß-MHC as their adult cardiac myosin, as in humans. Furthermore, HCM is a common disease in cats.68 A full-length human ß-MHC cDNA was incorporated into an adenoviral vector with a cytomegalovirus promoter and was expressed in adult feline cardiac myocytes. Electron microscopic examination of myocytes 48 hours after infection showed only minor changes in the structure of sarcomeres in cardiac myocytes. However, 120 hours after infection, approximately 50% of the myocytes infected with the mutant ß-MHC construct showed severe disruption of the sarcomere. In contrast, the structure of the sarcomere remained largely intact in myocytes transfected with normal ß-MHC construct.68
These studies have important implications for understanding the primary
defect and the pathogenesis of the phenotype. The results of
the in vitro studies are very compelling in that the mutant protein is
inherently defective as a contractile molecule. This is in accord with
our postulated hypothesis that the hypertrophy is
compensatory.61 63 This suggests that the
hypertrophy is similar to that occurring in response to
pressure or volume overload or, more appropriately, that of myocardial
infarction. The studies in COS cells and, more specifically, in feline
adult cardiac myocytes suggest sarcomere disarray to be an early
lesion. To further understand and confirm the significance of these
studies will require confirmation by other investigators and, more
important, documentation in the intact animal, as with overexpression
in transgenic animals, or with targeted mutations, such as with
replacement of genes by homologous recombination. A major obstacle
delaying both studies is the presence of -MHC in the mouse adult
heart compared with ß-MHC in human myocardium.
Nevertheless, if one assumes the mutant ß-MHC protein exhibits
impaired contractility and disrupts formation of the
normal sarcomeres, this would lead to increased stress encountered by
the normal contractile units and fibers, a stimulus known to induce
cardiac hypertrophy.
|
Evidence That Hypertrophy Is Compensatory in Familial HCM |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Hypertrophy is the common response of the heart to pressure overload. The mutant ß-MHC protein, with impaired contractility, may result in increased fiber stress that leads to compensatory hypertrophy. Evidence favoring the hypothesis that the hypertrophy is compensatory61 in response to the primary defect is as follows. (1) The phenotypes of HCM resulting from several distinct genes and a variety of mutations are similar, suggesting a common mechanism for the hypertrophy. (2) The disease occurs almost exclusively in the left ventricle, despite ß-MHC accounting for 35% of the myosin in the right and left ventricles. This suggests that the hypertrophy is secondary to an environmental stimulus such as the higher pressure and work load of the left ventricle. (3) Skeletal muscle, which also expresses the mutant ß-MHC, appears to have normal function in patients with HCM. Although this may reflect the differences in the quantity of the mutant myosin present in the heart and the skeletal muscles, it may also reflect the different physiological properties of these two organs. (4) The age-dependent manifestation of the cardiac hypertrophy of HCM indicates that the phenotype is secondary to environmental or other genetic factors. (5) The genes upregulated in pressure-overload–induced cardiac hypertrophy are also upregulated in the hypertrophied myocardium of patients with HCM, indicating a common hypertrophic response. Oncogenes, such as c-fos, c-jun, and c-myc, are upregulated, as are ANP and BNP in the hypertrophied myocardium of patients with HCM.85 86 87 (6) The phenotypic expression of hypertrophy in patients with HCM is influenced by the underlying genetic background in which mutations occur. Patients with HCM and ACE genotype DD are more likely to develop severe hypertrophy and involvement of the entire interventricular septum, apex, and lateral wall than are patients with ACE genotype II. These data indicate that the mutant protein harbinger of an impaired function triggers a cascade that induces the final phenotype of hypertrophy in patients with HCM.
|
Response of the Heart to Injury Is Limited to Hypertrophy, Dilatation, or a Combination |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
It is an important caveat to appreciate that the heart responds to injury, whether it is pressure overload, volume overload, loss of contractile mass (myocardial infarction), or inherited defects, by one of two mechanisms: hypertrophy, dilation (or a combination).41 This is why familial HCM, being a disease in which the heart responds only through hypertrophy, is important to an ultimate understanding of the hypertrophic response of the myocardium. The reciprocal disease is familial DCM, in which the heart responds predominantly by dilatation.88 Many inherited defects induce hypertrophy. Several mutations in the mitochondrial genome have been associated with cardiac hypertrophy.89 90 In mitochondrial DNA mutations, HCM is part of a general phenotypic expression of a systemic disease that is characterized by metabolic disorders and usually involves the central nervous and skeletal muscle systems. A characteristic feature of mitochondrial DNA mutation is the maternal inheritance of the disease, due to the inheritance of mitochondrial DNA only from the ovum. A confounding problem is establishing the causal relation of mitochondrial DNA mutations to HCM, due to the presence of enormous polymorphism in the mitochondrial DNA and a gradual increase in mitochondrial DNA mutations over time. Furthermore, the mitochondrial DNA content of different cells varies (heteroplasmy), with some cells showing mutations and others lacking that particular mutation.
No chromosomal locus has been identified for familial DCM90 ; however, DCM occurring in association with conduction defects91 has been mapped to chromosome 1p-1q, but the gene has not yet been identified. Several diseases of muscle, such as Duchenne's muscular dystrophy92 93 94 or myotonic dystrophy,95 96 that affect the heart secondarily induce DCM, as does the X-linked cardiomyopathy syndrome.97
The hypertrophy observed with acquired disorders (eg, from hypertension or from other inherited defects) does not show the myocyte or sarcomere disarray that is the hallmark of HCM previously referred to as IHSS. HCM as defined by the phenotype of myocardial hypertrophy in the absence of an increased load is also seen in overexpression studies in transgenic animals. Overexpression of calmodulin in the transgenic mouse induced a hypertrophic response in the myocardium.98 Similarly, overexpression of insulin-like growth factor–1, Ras, and Myf5 genes in transgenic mice also produced a phenotype of hypertrophy.99 100 However, no disruption of sarcomeric structure, a characteristic finding in HCM, was reported in these studies. Soon, through overexpression of transgenes or elimination of defective genes through homologous recombination, one can expect to identify the molecular basis for why cardiac hypertrophy occurs in one disease and dilatation occurs in another.
|
Perspective on the Pathogenesis of HCM |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Results from the in vitro studies strongly indicate that the primary defect is inherent in the mutant ß-MHC and is manifested as impaired contractility. Because there are so many different mutations in the ß-MHC gene, it is likely that mechanism(s) by which the mutations lead to impaired contractility will also be multiple. Until such hypotheses are confirmed in vivo, however, it is reasonable to assume that impaired contractility is the primary defect, regardless of the mechanism. How does such a defect lead to the hallmark of this disease as seen in the pathology of the myocardium, ie, hypertrophy, myocyte and sarcomere disarray, increased systolic function, and diastolic dysfunction?
The studies in the COS cells suggest filament assembly is impaired;
however, given that sarcomeres do not form in COS cells, even with
normal myosin, no implications for sarcomere formation can be deduced.
Results of studies in adult feline cardiac myocytes may reflect induced
breakdown of the formed sarcomeres, or the breakdown in sarcomere may
reflect the normal turnover of myosin, with the defect being the
inability to regenerate new sarcomeres. The defective protein may
destabilize the sarcomere through either increased turnover or impaired
binding of myosin to actin or through impaired interaction with other
proteins necessary for structural integrity. What is the stimulus for
increased protein synthesis (hypertrophy) by the myocyte?
We have shown previously that the ß-MHC protein synthesized by the
heart from an individual with HCM appears normal, as is the ratio of
ß-MHC to actin or to -MHC.101
In the studies in adult cardiac myocytes, it was also evident that the
filament formation was normal. It is reasonable to assume that the
increased breakdown of ß-MHC protein provides the stimulus for
compensatory hypertrophy. Presumably, the growth stimulus
is highly localized and may be modulated by autocrine factor(s) given
that hypertrophy is localized, in most patients, primarily
to the interventricular septum. Despite the hallmark of
extensive sarcomere and myocyte disarray, there is no clue as to why
this occurs or why it is primarily localized to the
ventricular septum. Similarly, there is no obvious reason
why systolic ventricular function is hyperdynamic.
Elucidation of the molecular basis for the pathogenesis of this disease
must provide a rationale for three puzzling consistent features
of the pathology: (1) predominance of hypertrophy in the
septum, (2) sarcomere and myocyte disarray, and (3) the supernormal
systolic function. The diastolic stiffness or decreased
compliance is expected with hypertrophy whether primary or
compensatory, but these other features are not typically seen in
compensatory hypertrophy such as that observed after
pressure or volume overload.
|
Significance of Identification and Characterization of HCM Mutations and Their Impact on the Practice of Cardiology |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Identification of the mutations responsible for HCM will provide an important diagnostic armamentarium. The present diagnosis of HCM occurs through echocardiographic detection of cardiac hypertrophy. This usually is not evident until puberty or later, whereas a genetic diagnosis is possible before or at any time after birth and requires only a blood sample. A characteristic of HCM is that the development of hypertrophy and its phenotypic expression are age dependent. This also is true for the diagnosis of HCM late in life for mutations that are associated with a low penetrance. Also, diseases such as hypertensive HCM in the elderly are indistinguishable from HCM by clinical criteria.19 Because HCM is an autosomal dominant disease, only half of the offspring of an affected individual will inherit the disease, and the other half will be normal. Thus, genetic screening through identification of the mutation will identify the individuals at risk of developing the disease before and independent of the presence of symptoms or the development of hypertrophy.
Genetic diagnosis will also provide prognostic information, as shown, particularly for the risk of SCD. This is particularly important as SCD often is the first manifestation of HCM and occurs frequently in apparently healthy young individuals.16 17 HCM is the most common cause of death in young competitive athletes.17 Although the clinical parameters of lack of syncope, lack of inducibility by electrophysiological testing, and lack of ischemia (in children) carry a favorable prognosis, none of the parameters when present alone or in combination have the desirable positive predictability. The need to determine whether an individual is at risk of subsequently developing HCM and possible SCD is greatest in children before the development of cardiac hypertrophy. The ability to identify and separate individuals with the mutation who are at risk of developing the disease from those without the mutation and therefore not at risk of developing the disease provides additional information that will supplement clinical ability to manage these patients. The indication for interventions such as implantable defibrillators should be decided after risk stratification based on many clinical as well as genetic variables that influence the outcome in patients with HCM. Therefore, genetic screening of members of a family affected with HCM will determine who is normal and who is likely to develop the disease as well as provide important prognostic data of particular importance for the children and asymptomatic individuals.
Screening for known mutations in individuals from a family affected with HCM is feasible but tedious, time consuming, and expensive. However, this is only possible for known mutations, whereas in a family in whom the disease is not due to a known mutation, chromosomal mapping and subsequent identification of the gene are required. Our preliminary studies indicate that the ß-MHC mutation is responsible for the occurrence of HCM in fewer than 20% of families with HCM.45 It is expected, however, that the techniques for mass genetic screening to identify known mutations will soon be automated. Thus, it is very likely that within the next few years, physicians will be able to routinely screen and identify genotype-positive individuals. Ultimately, if therapy such as gene transfer becomes available, genotyping will, of course, be essential.
|
Glimpses Into the Future |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
Elucidation of the molecular basis of HCM is expected to lead to a better understanding of its pathogenesis and is likely to provide a better therapeutic approach. It is believed that hypertrophy in HCM is a compensatory phenomenon that occurs in response to the presence of mutant myosin protein, the latter functioning as a poison peptide. Therefore, it is theoretically possible to induce regression of cardiac hypertrophy by inhibiting transcription of the mutant allele or translation of the mutant mRNA and abolishing the synthesis of the mutant poison peptide. The exact molecular pathogenesis of HCM remains to be determined, and thus definitive therapy based on genetic manipulation remains speculative. However, the heart renews itself every few weeks; the longest lasting protein, myosin, has a half-life of approximately 5 days. Thus, there is the inherent potential for corrective resynthesis. Inhibition of the defective gene, even in an adult with significant hypertrophy, could in weeks to months give rise to a normal heart. It is imperative that we continue to search for all of the genes and the mutations responsible for HCM so that comprehensive genetic screening of high school and college athletes, for example, will be possible as part of a goal to eliminate the early deaths of young athletes. It is important to recognize that most of these individuals have normal cardiac function until their death. Until such therapy is available, we must do everything possible, including the use of pacemakers and indwelling defibrillators, to bridge the gap. If the ACE gene plays even a remote role in the development of hypertrophy in HCM, a clinical trial with ACE inhibitors should be considered, at least in those without outflow tract obstruction.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported in part by grants from the National Heart, Lung, and Blood Institute, Specialized Centers of Research (P50-HL-42267-01); Bugher Foundation Center for Molecular Biology (86-2216); and the American Heart Association, Texas Affiliate (Grant-in-Aid 93G-1191). We greatly appreciate the secretarial assistance of Debora Weaver and Jacquilyn Valentine in the preparation of the manuscript and figures.
Received November 3, 1994; revision received January 4, 1995; accepted January 14, 1995.
|
References |
|---|
|
TopIntroductionClinical Epidemiology Genetic Basis of HCM...ß-MHC Protein and Its...ß-MHC Gene...Cardiac Troponin T and...Evidence That ß-MHC...Genotype-Phenotype Correlation...Influence of Environmental...Structure-Function Analysis of...Evidence That Hypertrophy Is...Response of the Heart...Perspective on the Pathogenesis...Significance of Identification...Glimpses Into the Future...References |
|---|
1. Cooperative Human Linkage Center (CHLC). A comprehensive human linkage map with centimorgan density. Science. 1994;265:2049-2054.
2. Weissenbach J, Gyapay G, Dib C, Vignal A, Morissette J, Millasseau P, Vaysseix G, Lathrop M. A second generation linkage map of the human genome. Nature. 1992;359:794-801. [Medline] [Order article via Infotrieve]
3. Weissenbach J. A second generation linkage map of the human genome based on highly informative microsatellite loci. Gene. 1994;135:275-278.
4. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet. 1989;44:388-396. [Medline] [Order article via Infotrieve]
5. Roberts R, Marian AJ, Bachinski LL. Overview: application of molecular biology to medical genetics. In: Markwald RR, Clark EB, Takao A, eds. Inborn Heart Disease—Developmental Mechanisms. Mount Kisco, NY: Futura Press; 1994:87-111.
6. Hejtmancik JF, Roberts R. Molecular genetics and application of linkage analysis. In: Roberts R, ed. Molecular Basis of Cardiology. Cambridge, UK: Blackwell Scientific Publications; 1993:355-381.
7. Mares A Jr, Towbin J, Bies RD, Roberts R. Current Problems in Cardiology: Molecular Biology for the Cardiologist. St Louis, Mo: Mosby-Year Book; 1992.
8. Marian AJ, Roberts R. Molecular genetics of hypertrophic cardiomyopathy. In: Coggins C, ed. Annual Review of Medicine. Palo Alto, Calif: Annual Reviews Inc; 1995:213-222.
9. Watkins H, MacRae C, Thierfelder L, Chou Y, Frenneaux MP, McKenna W, Seidman JG, Seidman CE. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet. 1993;3:333-337. [Medline] [Order article via Infotrieve]
10.
Thierfelder LC, MacRae C, Watkins H, Tomfohrde J,
McKenna W, Bom K, Noeske G, Schlepper M, Just J, Bowcock A, Vosberg
H-P, Seidman CE, Seidman JG. A familial hypertrophic
cardiomyopathy locus maps to chromosome
15q2. Proc Natl Acad Sci U S A. 1993;90:6270-6274.
11. Carrier L, Hengstenberg C, Beckmann JS, Guicheney P, Dufour C, Bercovici J, Dausse E, Berebbi-Bertrand I, Wisnewsky C, Pulvenis D, Fetler L, Vignal A, Weissenbach J, Hillaire D, Feingold J, Bouhour J, Hagege A, Desnos M, Isnard R, Dubourg O, Komajda M, Schwartz K. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet. 1993;4:311-313. [Medline] [Order article via Infotrieve]
12. Thierfelder L, Watkins H, MacRae C, Lamas R, McKinna W, Vosberg HP, Seidman JG, Seidman CE. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701-712. [Medline] [Order article via Infotrieve]
13. Towbin J, Roberts R. Cardiovascular diseases due to genetic abnormalities. In: Schlant RC, Alexander RW, eds. Hurst's The Heart: Arteries and Veins. New York, NY: McGraw Hill, Inc; 1994:1725-1759.
14. Roberts WC, Ferrans VJ, Kaltenbach M, Epstein SW, eds. Hypertrophic Cardiomyopathy: The Therapeutic Role of Calcium Antagonists. New York, NY: Springer-Verlag; 1982:59.
15.
Maron BJ, Roberts WC, Epstein SE. Sudden death
in hypertrophic cardiomyopathy: a profile of 78
patients. Circulation. 1982;65:1388-1394.
16. McKenna W, Deanfield J, Farugui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: role of age and clinical electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47:532-538. [Medline] [Order article via Infotrieve]
17. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7:204-214. [Abstract]
18. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315:610-614. [Abstract]
19. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277-283. [Abstract]
20. Maron BJ, Gardin JM, Flack JM, Gidding SS, Bild DE. How common is hypertrophic cardiomyopathy? Echocardiography identified prevalence in a general population of young adults (the CARDIA Study). Circulation. 1993;88(suppl I):I-452. Abstract.
21. Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, Takikawa R, Hasegawa I, Takahashi T, Suzuki J. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol. 1987;59:183-184. [Medline] [Order article via Infotrieve]
22.
Codd MB, Sugrue DD, Gersh BJ, Melton LJ III.
Epidemiology of idiopathic dilated and
hypertrophic cardiomyopathy: a population-based
study in Olmsted County, Minnesota, 1975–1984.
Circulation. 1989;80:564-572.
23. Agnarsson UT, Hardarson T, Hallgrimsson J, Sigfusson N. The prevalence of hypertrophic cardiomyopathy in men: an echocardiographic population screening study with a review of death records. J Intern Med. 1992;232:499-506. [Medline] [Order article via Infotrieve]
24. Savage DD, Castelli WP, Abbott RO, Garrison RJ, Anderson SJ, Kannel WB, Feinleib M. Hypertrophic cardiomyopathy and its markers in the general population: the great masquerader revisited: the Framingham Study. J Cardiovasc Ultrasonogr. 1983;2:41-47.
25. Liouville H. Retrecessment cardiaque sous aortique. Gazette Med Paris. 1869;24:161-165.
26. Teare RD. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1-10.
27. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis: a description of the disease based upon an analysis of 64 patients. Circulation. 1964;(suppl IV):IV-3-IV-119.
28.
Frank S, Braunwald E. Idiopathic hypertrophic
subaortic stenosis: clinical analysis of 126 patients
with emphasis on the natural history.
Circulation. 1968;37:759-788.
29. Clark CE, Henry WL, Epstein SE. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis. N Engl J Med. 1973;289:709-714.
30. van Dorp WG, Ten Cate FJ, Vletter WB, Dohmen H, Roelandt J. Familial prevalence of asymmetric septal hypertrophy. Eur J Cardiol. 1976;4:349-357. [Medline] [Order article via Infotrieve]
31. Maron BJ, Nichols PF III, Pickle LW, Wesley YE, Mulvihill JJ. Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol. 1984;53:1087-1094. [Medline] [Order article via Infotrieve]
32. Solomon SD, Simonette W, Watkins H, Ridker PM, Come P, McKenna WJ, Seidman CE, Lee RT. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the ß-myosin heavy chain gene. J Am Coll Cardiol. 1993;22:498-505. [Abstract]
33. Watkins H, Thierfelder L, Anan R, Jarcho JA, Matsumori A, McKenna W, Seidman JG, Seidman CE. Independent origin of identical ß cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. Am J Hum Genet. 1993;53:1180-1185. [Medline] [Order article via Infotrieve]
34. Jarcho JA, McKenna W, Pare JAP, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis-Keller H, Seidman JG, Seidman CE. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med. 1989;321:1372-1378. [Abstract]
35.
Hejtmancik JF, Brink PA, Towbin J, Hill R, Brink L,
Tapscott T, Traktenbroit A, Roberts R. Localization of the gene
for familial hypertrophic cardiomyopathy to
chromosome 14q1 in a diverse US population.
Circulation. 1991;83:1592-1597.
36. Geisterfer-Lawrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a beta-cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006. [Medline] [Order article via Infotrieve]
37. Rosenzweig A, Watkins H, Hwang D, Miri M, McKenna W, Traill T, Seidman JG, Seidman CE. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med. 1991;325:1753-1760. [Abstract]
38. Watkins H, Rosenzweig A, Hwang D, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114. [Abstract]
39. Marian AJ, Yu QT, Mares A Jr, Hill R, Roberts R, Perryman MB. Detection of a new mutation in the ß-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. J Clin Invest. 1992;90:2156-2165.
40. Dausse E, Komajda M, Fetler L, Dubourg O, Dufour C, Carrier L, Wisnewsky C, Bercovici J, Hengstenberg C, Al-Mahdawi S, Isnard R, Hagege A, Bouhour J, Desnos M, Beckmann J, Weissenbach J, Schwartz K, Guicheney P. Familial hypertrophic cardiomyopathy: microsatellite haplotyping and identification of a hot spot for mutations in the ß-myosin heavy chain gene. J Clin Invest. 1993;92:2807-2813.
41. Roberts R, Bachinski LL, Yu QT, Quiñones MA, Young R, Marian AJ. Molecular analysis of genotype/phenotype correlations of hypertrophic cardiomyopathy. In: Dhalla NS, Singal PK, Beamish RE, eds. Heart Hypertrophy and Failure. Boston, Mass: Kluwer Academic Publishers; 1995.
42.
Epstein ND, Fananapazir L, Lin HJ, Mulvihill J, White
R, LaLouel JM, Lipton RP, Nunhuis AW, Leppert M. Evidence of
genetic heterogeneity in five kindreds with familial
hypertrophic cardiomyopathy.
Circulation. 1992;85:635-647.
43.
Schwartz K, Beckmann J, Dufour C, Faure L,
Fougerousse F, Carrier L, Hengstenberg C, Cohen D, Vosberg HP, Sacrez
A. Exclusion of cardiac myosin heavy chain and actin gene
involvement in hypertrophic cardiomyopathy of
several French families. Circ Res. 1992;71:3-8.
44. Bachinski LL, Czernuszewicz G, Elstein E, Webber S, Hill R, Schwartz K, Rakowski H, Wigle ED, Sole MJ, Hejtmancik JF, Perryman MB, Roberts R. Identification of a Canadian family with hypertrophic cardiomyopathy that it is not genetically linked to chromosome 14 locus using polymorphic satellite markers. Circulation. 1992;86(suppl I):I-230. Abstract.
45. Abchee AB, Greve G, Ifegwu J, Joseph A, Bachinski LL, Roberts R. Rapid genetic screen for common ß-myosin heavy chain mutations causing familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 1995; Special Issue:26A. Abstract.
46.
Ferraro M, Scarton G, Ambrosini M.
Cosegregation of hypertrophic cardiomyopathy
and a fragile site on chromosome 16 in a large Italian family.
J Med Genet. 1990;27:363-366.
47. Nishi H, Kimura A, Sasaki M, Wakisaka A, Matsuyama K, Koga Y, Toshima H, Sasazuki T. Localization of the gene for hypertrophic cardiomyopathy to chromosome 18q. Circulation. 1989;80(suppl II):II-457. Abstract.
48. Matsuoka R, Yoshida MC, Kanda N, Kimura M, Ozasa H, Takao A. Human cardiac myosin heavy chain gene mapped within chromosome region 14q11.2-q13. Am J Med Genet. 1989;32:279-284. [Medline] [Order article via Infotrieve]
49.
Liew CC, Sole MJ, Yamauchi-Takihara K, Kellam B,
Anderson DH, Lin L, Liew JC. Complete sequence and organization
of the human cardiac ß-myosin heavy chain gene.
Nucleic Acids Res. 1990;18:3647-3651.
50. Jaenicke T, Diedrich KW, Haas W, Schleich J, Lichter P, Pfordt M, Bach A, Vosberg HP. The complete sequence of the human heavy chain gene and a comparative analysis of its product. Genomics. 1990;8:194-206. [Medline] [Order article via Infotrieve]
51. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev. 1986;3:710-760.
52.
Mercadier JJ, Bouveret P, Gorza L, Schiaffino S,
Clark WA, Zak R, Swynghedauw B, Schwartz K. Myosin isoenzymes in
normal and hypertrophied human ventricular
myocardium. Circ Res. 1983;53:52-62.
53.
Rayment I, Rypniewski RW, Schmidt-Base K, Smith R,
Tomchick DR, Benning MM, Winkelmann DA, Wesenberg G, Holden HM.
Three-dimensional structure of myosin subfragment-1: a
molecular motor. Science. 1993;261:50-58.
54. Ishijima A, Harada Y, Kojima H, Funatsu T, Higuchi H, Yanagida T. Single-molecule analysis of the actomyosin motor using nano-manipulation. Biochem Biophys Res Commun. 1994;199:1057-1063. [Medline] [Order article via Infotrieve]
55. Vale RD. Getting a grip on myosin. Cell. 1994;78:733-737. [Medline] [Order article via Infotrieve]
56. Finer JT, Simmons RM, Spudich JA. Single myosin mechanics: picoNewton forces and nanometer steps. Nature. 1994;368:113-119. [Medline] [Order article via Infotrieve]
57. Townsend PJ, Farza H, MacGeon C, Spurr NK, Wade R, Gahlmann R, Yacoub MH, Barton PJR. Human cardiac troponin T: identification of fetal isoforms and assignment of the TNNT2 locus to chromosome 1q. Genomics. 1994;21:311-316. [Medline] [Order article via Infotrieve]
58. Breitbart RE, Nguyen HT, Medford RM, Destree AT, Mahdavi V, Nadal-Ginard B. Intricate combinatorial patterns of exon splicing generate multiple regulated troponin T isoforms from a single gene. Cell. 1985;41:67-82. [Medline] [Order article via Infotrieve]
59. Zot AS, Potter JD. Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu Rev Biochem. 1987;16:535-559.
60.
Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R,
O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG, Seidman
CE. Mutations in the genes for cardiac troponin T and
-tropomyosin in hypertrophic
cardiomyopathy. N Engl J
Med. 1995;332:1058-1064.
61. Perryman MB, Yu QT, Marian AJ, Mares A Jr, Czernuszewicz G, Ifegwu J, Hill R, Roberts R. Expression of a missense mutation in the mRNA for ß-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. J Clin Invest. 1992;90:271-277.
62. Greve G, Bachinski LL, Friedman DL, Czernuszewicz G, Anan R, Towbin JA, Seidman CE, Roberts R. Isolation of a de novo mutant myocardial ßMHC protein in a pedigree with hypertrophic cardiomyopathy. Hum Mol Genet. 1994;3:2073-2075.
63.
Yu QT, Ifegwu J, Marian AJ, Mares A Jr, Hill R,
Perryman MB, Bachinski LL, Roberts R. Hypertrophic
cardiomyopathy mutation is expressed in mRNA of
skeletal as well as cardiac muscle.
Circulation. 1993;87:406-412.
64. Cuda G, Fananapazir L, Zhu W, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of ß myosin in hypertrophic cardiomyopathy. J Clin Invest. 1993;91:2861-2865.
65. Cuda G, Sellers J, Epstein ND, Fananapazir L. In-vitro motility activity of ß-cardiac myosin depends on the nature of the ß-myosin heavy chain gene mutations in hypertrophic cardiomyopathy. Circulation. 1993;88(suppl I):I-343. Abstract.
66.
Watkins H, Anan R, Coviello DA, Spirito P, Seidman
JG, Seidman CE. A de novo mutation in -tropomyosin that
causes hypertrophic cardiomyopathy.
Circulation. 1995;91:2302-2305.
67.
Sweeney HL, Straceski AJ, Leinwand LA, Tikunov BA,
Faust L. Heterologous expression of a
cardiomyopathic myosin that is defective in its actin
interaction. J Biol Chem. 1994;269:1603-1605.
68.
Marian AJ, Yu QT, Mann DL, Graham FL, Roberts R.
Expression of a mutation causing hypertrophic
cardiomyopathy in adult feline cardiocytes
disrupts sarcomere assembly in adult feline cardiac myocytes.
Circ Res. 1995;77:98-106.
69. Maron BJ, Lipson LC, Roberts WC, Savage DD, Epstein SE. `Malignant' hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death. Am J Cardiol. 1978;41:1133-1140. [Medline] [Order article via Infotrieve]
70.
Roberts R. Molecular genetics: therapy or
terror? Circulation. 1994;89:499-502.
71. Anan R, Greve G, Thierfelder L, Watkins HC, McKenna WJ, Solomon S, Vecchio C, Shono H, Nakao S, Tanaka H, Mares A Jr, Towbin JA, Spirito P, Roberts R, Seidman JG, Seidman CE. Prognostic implications of novel ß cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280-285.
72.
Marian AJ, Mares A Jr, Kelly DP, Yu QT, Abchee AB,
Hill R, Roberts R. Sudden cardiac death in hypertrophic
cardiomyopathy: variability in phenotypic
expression of ß-myosin heavy chain mutations. Eur
Heart J. 1995;16:368-376.
73.
Epstein ND, Cohn GM, Cyran F, Fananapazir L.
Differences in clinical expression of hypertrophic
cardiomyopathy associated with two distinct
mutations in the ß-myosin heavy chain gene: a 908 Leu-Val
mutation and a 403 Arg-Gln mutation.
Circulation. 1992;86:345-352.
74.
Fananapazir L, Epstein ND.
Genotype-phenotype correlations in
hypertrophic cardiomyopathy: insights provided by
comparisons of kindreds with distinct and identical ß-myosin
heavy chain gene mutations. Circulation. 1994;89:22-32.
75. Marian AJ. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers. Clin Cardiol. 1995;18:189-198. [Medline] [Order article via Infotrieve]
76. Traeger L, Mackenzie JM Jr, Epstein HF, Goldstein MA. Transition in the thin-filament arrangement in rat skeletal muscle. J Muscle Res Cell Motil. 1983;4:353-366. [Medline] [Order article via Infotrieve]
77. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet. 1993;342:1085-1086. [Medline] [Order article via Infotrieve]
78. Lechin M, Yu QT, Workman R, Greve G, Roberts R. Angiotensin converting enzyme genotype DD is associated with increased left ventricular mass in patients with hypertrophic cardiomyopathy. Circulation. 1994;90(suppl I):I-174. Abstract.
79. Linz W, Schaper J, Wiemer G, Albus U, Scholkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one-year study in rats. Br J Pharmacol. 1992;107:970-975. [Medline] [Order article via Infotrieve]
80.
Sadoshima J, Izumo S. Molecular
characterization of angiotensin II induced
hypertrophy or cardiac myocytes and hyperplasia of cardiac
fibrolasts: critical role of the AT1 receptor subtype.
Circ Res. 1993;73:413-423.
81.
Friedrich SP, Lorell BH, Rousseau MF, Hayashida W,
Hess OM, Douglas PS, Gordon S, Keighley CS, Benedict C, Krayenbuehl HP,
Grossman W, Pouleur H. Intracardiac
angiotensin-converting enzyme inhibition improves
diastolic function in patients with left
ventricular hypertrophy due to aortic
stenosis. Circulation. 1994;90:2761-2771.
82. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing ß-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest. 1995;95:1409-1414.
83.
Straceski AJ, Geisterfer-Lawrance AA, Seidman CE,
Seidman JG, Leinwand LA. Functional analysis of myosin
missense mutations in familial hypertrophic
cardiomyopathy. Proc Natl Acad Sci
U S A. 1994;91:589-593.
84. Vikstrom KL, Rovner AS, Saez CG, Bravo-Zehnder M, Straceski AJ, Leinwand LA. Sarcomeric myosin heavy chain expressed in nonmuscle cells forms thick filaments in the presence of substoichiometric amounts of light chains. Cell Motil Cytoskeleton. 1993;26:193-204.
85. Hengstenberg C, Maisch B. Increased nuclear proto-oncogene expression in hypertrophic cardiomyopathy. Cardioscience. 1993;4:15-20. [Medline] [Order article via Infotrieve]
86. Derchi G, Bellone P, Chiarella F, Randazzo M, Zino V, Vecchi C. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:1502-1504. [Medline] [Order article via Infotrieve]
87.
Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara
T, Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S.
Ventricular expression of brain
natriuretic peptide in hypertrophic
cardiomyopathy.
Circulation. 1993;88:372-380.
88. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, Burnett JC, Rodeheffer RJ, Chesebro JH, Tazelaar HD. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326:77-82. [Abstract]
89. Ozawa T, Tanaka M, Sugiyama S, Hattori K, Ito T, Ohno K, Takahashi A, Sato W, Takada G, Mayumi B. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic or dilated cardiomyopathy. Biochem Biophys Res Commun. 1990;170:830-836. [Medline] [Order article via Infotrieve]
90.
Kelly DP, Strauss AW. Inherited
cardiomyopathies. N Engl J
Med. 1994;330:913-919.
91. Kass S, MacRae C, Graber HL, Sparks EA, McNamara D, Boudoulas H, Basson CT, Baker PB III, Cody RJ, Fishman MC, Cox N, Kong A, Wooley CF, Seidman JG, Seidman CE. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1. Nat Genet. 1994;7:546-551. [Medline] [Order article via Infotrieve]
92.
Bies RD, Friedman DL, Roberts R, Perryman MB, Caskey
CT. Expression and localization of dystrophin in human cardiac
Purkinje fibers. Circulation. 1992;86:147-153.
93. Bies RD, Caskey CT, Fenwick R. An intact cysteine-rich domain is required for dystrophin function. J Clin Invest. 1992;90:666-672.
94. Bies RD, Phelps SF, Cortez MD, Roberts R, Caskey CT, Chamberlain JS. Dystrophin mRNA transcripts are differentially expressed during heart, skeletal muscle, and brain development. Circulation. 1991;84(suppl II):II-H. Abstract.
95.
Fu Y, Friedman DL, Richards S, Pearlman JA, Gibbs RA,
Pizzuti A, Ashizawa T, Perryman MB, Scarlato G, Fenwick RG Jr, Caskey
CT. Decreased expression of myotonin-protein kinase mRNA and
protein in adult form of myotonic dystrophy.
Science. 1993;260:235-238.
96. Fu YH, Friedman DL, Richards S, Pearlman JA, Gibbs R, Pizzuti A, Ashizawa T, Perryman MB, Fenwick RG, Caskey CT. Varying expression of myotonin protein kinase mRNA and protein levels in the adult myotonic dystrophy. Science. 1993;72:971-983.
97.
Towbin JA, Hejtmancik JF, Brink P, Gelb BD, Zhu XM,
Chamberlain JS, McCabe ERB, Swift M. X-linked dilated
cardiomyopathy (XLCM): molecular genetic evidence
of linkage to the Duchenne muscular dystrophy gene at the Xp21
locus. Circulation. 1993;87:1854-1865.
98.
Gruver CL, DeMayo F, Goldstein MA, Means AR.
Targeted developmental overexpression of calmodulin
induces proliferative and hypertrophic growth of
cardiomyocytes in transgenic mice.
Endocrinology. 1993;133:376-388.
99. Hunter JJ, Rockman HA, Chien KR. Left ventricular hypertrophy produced by tissue-targeted expression of activated Ras in transgenic mice. Circulation. 1994;90(suppl I):I-197. Abstract.
100. Edwards J, Schlais S, Lyons G, Malhotra A, Smith C, Santerre R, Bales K, Factor S, Leinwand L. Cardiomyopathy in transgenic Myf5 mice. Circulation. 1994;90(suppl I):I-579. Abstract.
101.
Vybiral T, Roberts R, Deitiker PR, Epstein HF.
Accumulation and assembly of myosin in the Arg-Gln ß—MHC
hypertrophic cardiomyopathy mutant.
Circ Res. 1992;71:1404-1409.
This article has been cited by other articles:
 |
|
 |
|
  B. J. Maron, J.G. Seidman, and C. E. Seidman Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2125 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Nishimura and D. R. Holmes Jr. Hypertrophic Obstructive Cardiomyopathy N. Engl. J. Med., March 25, 2004; 350(13): 1320 - 1327. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gilbert-Barness Metabolic Cardiomyopathy and Conduction System Defects in Children Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 15 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Garcia-Castro, J. R. Reguero, A. Batalla, B. Diaz-Molina, P. Gonzalez, V. Alvarez, A. Cortina, G. I. Cubero, and E. Coto Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the {beta}-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients Clin. Chem., August 1, 2003; 49(8): 1279 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Van Driest, E. G. Ellsworth, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy * Note Added in Proof Circulation, July 29, 2003; 108(4): 445 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maron Hypertrophic Cardiomyopathy: A Systematic Review JAMA, March 13, 2002; 287(10): 1308 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J R Ortlepp, H P Vosberg, S Reith, F Ohme, N G Mahon, D Schroder, H G Klues, P Hanrath, and W J McKenna Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene Heart, March 1, 2002; 87(3): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Hardt, Y.-J. Geng, O. Montagne, K. Asai, C. Hong, G. P. Yang, S. P. Bishop, S.-J. Kim, D. E. Vatner, C. E. Seidman, et al. Accelerated Cardiomyopathy in Mice With Overexpression of Cardiac Gs{alpha} and a Missense Mutation in the {alpha}-Myosin Heavy Chain Circulation, February 5, 2002; 105(5): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Niimura, K. K. Patton, W. J. McKenna, J. Soults, B. J. Maron, J.G. Seidman, and C. E. Seidman Sarcomere Protein Gene Mutations in Hypertrophic Cardiomyopathy of the Elderly Circulation, January 29, 2002; 105(4): 446 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts and U. Sigwart New Concepts in Hypertrophic Cardiomyopathies, Part I Circulation, October 23, 2001; 104(17): 2113 - 2116. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, H. Niimura, S. A. Casey, M. K. Soper, G. B. Wright, J. G. Seidman, and C. E. Seidman Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations J. Am. Coll. Cardiol., August 1, 2001; 38(2): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Nagueh, S. J. Stetson, N. M. Lakkis, D. Killip, A. Perez-Verdia, M. L. Entman, W. H. Spencer III, and G. Torre-Amione Decreased Expression of Tumor Necrosis Factor-{{alpha}} and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy Circulation, April 10, 2001; 103(14): 1844 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Mazur, S. F. Nagueh, N. M. Lakkis, K. J. Middleton, D. Killip, R. Roberts, and W. H. Spencer III Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy Circulation, March 20, 2001; 103(11): 1492 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziegelhoffer, P. S Tappia, N. Mesaeli, N. Sahi, N. S Dhalla, and V. Panagia Low level of sarcolemmal phosphatidylinositol 4,5-bisphosphate in cardiomyopathic hamster (UM-X7.1) heart Cardiovasc Res, January 1, 2001; 49(1): 118 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Varnava, P M Elliott, S Sharma, W J McKenna, and M J Davies Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease Heart, November 1, 2000; 84(5): 476 - 482. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. C. Evans, J. R. Pena, R. M. Phillips, M. Muthuchamy, D. F. Wieczorek, R. J. Solaro, and B. M. Wolska Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2414 - H2423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Spencer III and R. Roberts Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy : The Need for a Registry Circulation, August 8, 2000; 102(6): 600 - 601. [Full Text] [PDF]
|
|
|
|
|
|
W. L. Atiga, L. Fananapazir, D. McAreavey, H. Calkins, and R. D. Berger Temporal Repolarization Lability in Hypertrophic Cardiomyopathy Caused by {beta}-Myosin Heavy-Chain Gene Mutations Circulation, March 21, 2000; 101(11): 1237 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shirani, R. Pick, W. C. Roberts, and B. J. Maron Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death J. Am. Coll. Cardiol., January 1, 2000; 35(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Muraishi, H Kai, K Adachi, H Nishi, and T Imaizumi Malalignment of the sarcomeric filaments in hypertrophic cardiomyopathy with cardiac myosin heavy chain gene mutation Heart, November 1, 1999; 82(5): 625 - 629. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Muthuchamy, K. Pieples, P. Rethinasamy, B. Hoit, I. L. Grupp, G. P. Boivin, B. Wolska, C. Evans, R. J. Solaro, and D. F. Wieczorek Mouse Model of a Familial Hypertrophic Cardiomyopathy Mutation in {alpha}-Tropomyosin Manifests Cardiac Dysfunction Circ. Res., July 9, 1999; 85(1): 47 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Olivotto, B. J. Maron, A. Montereggi, F. Mazzuoli, A. Dolara, and F. Cecchi Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2044 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yanaga, S. Morimoto, and I. Ohtsuki Ca2+ Sensitization and Potentiation of the Maximum Level of Myofibrillar ATPase Activity Caused by Mutations of Troponin T Found in Familial Hypertrophic Cardiomyopathy J. Biol. Chem., March 26, 1999; 274(13): 8806 - 8812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ahmad, D. Li, A. Karibe, O. Gonzalez, T. Tapscott, R. Hill, D. Weilbaecher, P. Blackie, M. Furey, M. Gardner, et al. Localization of a Gene Responsible for Arrhythmogenic Right Ventricular Dysplasia to Chromosome 3p23 Circulation, December 22, 1998; 98(25): 2791 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Spooner, M. P. Perry, R. O. Brandenburg, and G. D. Pennock Increased intraventricular velocities: An unrecognized cause of systolic murmur in adults J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1589 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jaaskelainen, M. Soranta, R. Miettinen, L. Saarinen, J. Pihlajamaki, K. Silvennoinen, T. Tikanoja, M. Laakso, and J. Kuusisto The cardiac {beta}-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1709 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, J. H. Moller, C. E. Seidman, G. M. Vincent, H. C. Dietz, A. J. Moss, J. A. Towbin, H. M. Sondheimer, R. E. Pyeritz, G. McGee, et al. Impact of Laboratory Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Diseases: Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome : A Statement for Healthcare Professionals From the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association Circulation, October 6, 1998; 98(14): 1460 - 1471. [Full Text] [PDF]
|
|
|
|
|
|
H. Kai, A. Muraishi, Y. Sugiu, H. Nishi, Y. Seki, F. Kuwahara, A. Kimura, H. Kato, and T. Imaizumi Expression of Proto-oncogenes and Gene Mutation of Sarcomeric Proteins in Patients With Hypertrophic Cardiomyopathy Circ. Res., September 21, 1998; 83(6): 594 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Charron, O. Dubourg, M. Desnos, M. Bennaceur, L. Carrier, A.-C. Camproux, R. Isnard, A. Hagege, J. M. Langlard, G. Bonne, et al. Clinical Features and Prognostic Implications of Familial Hypertrophic Cardiomyopathy Related to the Cardiac Myosin-Binding Protein C Gene Circulation, June 9, 1998; 97(22): 2230 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fougerousse, A.-L. Delezoide, M. Y. Fiszman, K. Schwartz, J. S. Beckmann, and L. Carrier Cardiac Myosin Binding Protein C Gene Is Specifically Expressed in Heart During Murine and Human Development Circ. Res., January 23, 1998; 82(1): 130 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Izawa, M. Yokota, Y. Takeichi, M. Inagaki, K. Nagata, M. Iwase, and T. Sobue Adrenergic Control of the Force-Frequency and Relaxation-Frequency Relations in Patients With Hypertrophic Cardiomyopathy Circulation, November 4, 1997; 96(9): 2959 - 2968. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Marian, G. Zhao, Y. Seta, R. Roberts, and Q.-t. Yu Expression of a Mutant (Arg92Gln) Human Cardiac Troponin T, Known to Cause Hypertrophic Cardiomyopathy, Impairs Adult Cardiac Myocyte Contractility Circ. Res., July 19, 1997; 81(1): 76 - 85. [Abstract] [Full Text]
|
|
|
|
|
|
P. Spirito, C. E. Seidman, W. J. McKenna, and B. J. Maron The Management of Hypertrophic Cardiomyopathy N. Engl. J. Med., March 13, 1997; 336(11): 775 - 785. [Full Text] [PDF]
|
|
|
|
|
|
J.-F. Forissier, L. Carrier, H. Farza, G. Bonne, J. Bercovici, P. Richard, B. Hainque, P. J. Townsend, M. H. Yacoub, S. Faure, et al. Codon 102 of the Cardiac Troponin T Gene Is a Putative Hot Spot for Mutations in Familial Hypertrophic Cardiomyopathy Circulation, December 15, 1996; 94(12): 3069 - 3073. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Roden, R. Lazzara, M. Rosen, P. J. Schwartz, J. Towbin, and G. M. Vincent Multiple Mechanisms in the Long-QT Syndrome: Current Knowledge, Gaps, and Future Directions Circulation, October 15, 1996; 94(8): 1996 - 2012. [Abstract] [Full Text]
|
|
|
|
|
|
M. L. Schwartz, G. F. Cox, A. E. Lin, M. S. Korson, A. Perez-Atayde, R. V. Lacro, and S. E. Lipshultz Clinical Approach to Genetic Cardiomyopathy in Children Circulation, October 15, 1996; 94(8): 2021 - 2038. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||